Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cromoglicate→

Cromoglicate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
16110-51-3
Molecular formula
C23H16O11
Molecular weight
468.4 g/mol
Drug class
Mast-cell stabiliseranti-allergic agent (cromoglicic acid)
Mechanism of action
Inhibits activation and mediator release from sensitised mast cells and other inflammatory cells. The precise molecular mechanism is not fully established; it acts prophylactically and is not a rapid bronchodilator. Sodium cromoglicate is a salt of the same active moiety.
Indications / reported uses
  • Prevention of bronchial asthma symptoms with inhaled formulations
  • Treatment or prevention of allergic rhinitis with nasal formulations
  • Relief of allergic conjunctivitis with ophthalmic formulations
  • Selected systemic use for mastocytosis with oral formulations; use is route- and product-specific

Sources: US DailyMed — Cromolyn sodium products · NHS — Sodium cromoglicate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cromoglicate Environmental Risk Assessment (ERA) (the Cromoglicate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.